OncoMatch/Clinical Trials/NCT06350318
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Is NCT06350318 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Zanubrutinib and Rituximab for follicular lymphoma.
Treatment: Zanubrutinib · Rituximab — The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+)
Documentation of CD20+ status
Disease stage
Required: Stage II, IIE, II2, III, IV
disease requiring systemic therapy rather than local radiation (ie, stage II only if not eligible for radiation therapy or with stage III/IV); gastric MZL only if advanced stage disease requiring systemic therapy (e.g., stage IIE, II2, IV- supradiaphragmatic nodal or disseminated extranodal disease such as bone marrow or additional extra nodal sites)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Prior therapy for lymphoma including chemotherapy or immunotherapy
Cannot have received: immunotherapy
Prior therapy for lymphoma including chemotherapy or immunotherapy
Cannot have received: BTK inhibitor
Prior exposure to a BTK inhibitor
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
All participants must have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06350318 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIE or II2 or III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages